摘要
目的 探讨己酮可可碱缓释片治疗糖尿病足的经济性。方法 基于卫生体系角度,利用Treeage Pro 2011软件构建为期20周的决策树模型,对己酮可可碱缓释片与常规方法治疗糖尿病足进行成本-效果分析,并利用敏感性分析判断结果的稳健性。临床效果指标采用截肢率,数据来源于单篇随机对照试验(RCT),成本数据来源于药智网。结果 己酮可可碱缓释片与常规治疗相比,治疗糖尿病时成本低,效果高,增量成本-效果比(ICER)<0。敏感性分析结果表明,对基础分析结果影响最大的因素是未行截肢手术的住院天数,且在患者意愿支付(WTP)阈值变动范围内,己酮可可碱缓释片的可接受概率始终高于常规治疗。说明成本-效果分析结果稳健性良好。结论 己酮可可碱缓释片治疗糖尿病足,与常规治疗相比具有成本-效果优势,能为临床治疗方案选择和国家医保政策决策提供参考依据。
Objective To evaluate the economic efficiency of pentoxifylline sustained-release tablets in the treatment of diabetic foot. Methods Based on the perspective of health system, Treeage Pro software was used to build a 20-week decision tree model.The cost-effectiveness analysis of pentoxifylline sustained release tablet and conventional treatment for diabetic foot were carried out, and sensitivity analysis was used to judge the robustness of the results.Amputation rate was used as the clinical efficacy index,the data was collected from a randomized controlled trial, and the cost data was collected from the yaozhi website. Results Compared with conventional treatment, pentoxifylline sustained-release tablets had lower cost and higher efficacy in the treatment of diabetic foot, and ICER<0. The results of sensitivity analysis showed that the most important factor affecting the results of basic analysis was the number of days in hospital without amputation, and within the range of patients’ willingness to pay, the acceptability probability of pentoxifylline sustained-release tablets was always higher than that of conventional treatment.It showed that the results of cost-effectiveness analysis were robust. Conclusion Ketotheobromine sustained-release tablets in the treatment of diabetic foot has cost-effectiveness advantages compared with conventional treatment, and can provide reference for clinical treatment program selection and national medical insurance policy decision-making.
作者
李雪靖
高胜男
刘国强
LI Xue-Jing;GAO Sheng-Nan;LIU Guo-Qiang(Department of pharmacy,the Third Hospital of Hebei Medical University,Shijiangzhuang 050000,China;Hebei Medicine and Health Technology Assessment Association,Shijiangzhuang 050000,China)
出处
《中国药物经济学》
2022年第8期11-15,共5页
China Journal of Pharmaceutical Economics
